JP6094578B2 - 代謝性障害の治療のためのgpr119モジュレーターとしての置換ピペリジン - Google Patents
代謝性障害の治療のためのgpr119モジュレーターとしての置換ピペリジン Download PDFInfo
- Publication number
- JP6094578B2 JP6094578B2 JP2014514056A JP2014514056A JP6094578B2 JP 6094578 B2 JP6094578 B2 JP 6094578B2 JP 2014514056 A JP2014514056 A JP 2014514056A JP 2014514056 A JP2014514056 A JP 2014514056A JP 6094578 B2 JP6094578 B2 JP 6094578B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituted
- phenyl
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CNCCC1=*C(I)=*1 Chemical compound CNCCC1=*C(I)=*1 0.000 description 23
- MSAXWXFCWGHFFL-UHFFFAOYSA-N CC(C)c1n[o]c(N(CC2)CCC2NC2CC2)n1 Chemical compound CC(C)c1n[o]c(N(CC2)CCC2NC2CC2)n1 MSAXWXFCWGHFFL-UHFFFAOYSA-N 0.000 description 2
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 2
- RGTBLCLLSZPOKR-UHFFFAOYSA-N Cc1ncn[o]1 Chemical compound Cc1ncn[o]1 RGTBLCLLSZPOKR-UHFFFAOYSA-N 0.000 description 2
- QNKSWMYLUSPYAZ-AAPHRLRXSA-N C/C(/N(c(cc1)ncc1C(N(C1CC1)C(CCN(C1)c2ccc(C(F)(F)F)cn2)C1F)=O)N)=N/N Chemical compound C/C(/N(c(cc1)ncc1C(N(C1CC1)C(CCN(C1)c2ccc(C(F)(F)F)cn2)C1F)=O)N)=N/N QNKSWMYLUSPYAZ-AAPHRLRXSA-N 0.000 description 1
- OYCDNJIQKNTDFR-UHFFFAOYSA-N C=Cc1ncccc1F Chemical compound C=Cc1ncccc1F OYCDNJIQKNTDFR-UHFFFAOYSA-N 0.000 description 1
- KEKUKSKHQBPTSR-UHFFFAOYSA-N CC(C)c1n[o]c(N(CC2)CCC2=O)n1 Chemical compound CC(C)c1n[o]c(N(CC2)CCC2=O)n1 KEKUKSKHQBPTSR-UHFFFAOYSA-N 0.000 description 1
- HTUYWKYIIKVIDH-UHFFFAOYSA-N CCC(CC)=C/N=C(\N)/N(CC1)CCC1N(C1CC1)C(c(nc1)cnc1-[n]1ncnc1)=O Chemical compound CCC(CC)=C/N=C(\N)/N(CC1)CCC1N(C1CC1)C(c(nc1)cnc1-[n]1ncnc1)=O HTUYWKYIIKVIDH-UHFFFAOYSA-N 0.000 description 1
- CEAUPHHUNPGPRD-UHFFFAOYSA-N CCOc(cc1)ncc1-c(nc1)ncc1C(N(C1CC1)C1CCNCC1)=O Chemical compound CCOc(cc1)ncc1-c(nc1)ncc1C(N(C1CC1)C1CCNCC1)=O CEAUPHHUNPGPRD-UHFFFAOYSA-N 0.000 description 1
- KLCSEFGJARHHPI-UHFFFAOYSA-N CCc1cnc(N(CC2)CCC2=O)nc1 Chemical compound CCc1cnc(N(CC2)CCC2=O)nc1 KLCSEFGJARHHPI-UHFFFAOYSA-N 0.000 description 1
- PCBRKNRKGSLBES-UHFFFAOYSA-N CCc1cnc(N(CC2)CCC2N(C2CC2)C(c2ccc(-[n]3cncc3)nn2)=O)nc1 Chemical compound CCc1cnc(N(CC2)CCC2N(C2CC2)C(c2ccc(-[n]3cncc3)nn2)=O)nc1 PCBRKNRKGSLBES-UHFFFAOYSA-N 0.000 description 1
- FEZOYGSDMSGLKF-UHFFFAOYSA-N CCc1cnc(N(CC2)CCC2N(C2CC2)C(c2cnc(-[n]3c(C)ncc3)nc2)=O)nc1 Chemical compound CCc1cnc(N(CC2)CCC2N(C2CC2)C(c2cnc(-[n]3c(C)ncc3)nc2)=O)nc1 FEZOYGSDMSGLKF-UHFFFAOYSA-N 0.000 description 1
- ZXENSRNGQLLLQP-RBUKOAKNSA-N CCc1cnc(N(CC[C@H]2N(C3CC3)C(c(cc3)cnc3-[n]3nnnc3C)=O)C[C@@H]2F)nc1 Chemical compound CCc1cnc(N(CC[C@H]2N(C3CC3)C(c(cc3)cnc3-[n]3nnnc3C)=O)C[C@@H]2F)nc1 ZXENSRNGQLLLQP-RBUKOAKNSA-N 0.000 description 1
- CZQSEYWYGNEWBZ-RMSVRTADSA-N CCc1cnc(N(CC[C@H]2N(C3CC3)C(c(cc3)cnc3N3N=C[N-]C3C)=O)C[C@@H]2F)nc1 Chemical compound CCc1cnc(N(CC[C@H]2N(C3CC3)C(c(cc3)cnc3N3N=C[N-]C3C)=O)C[C@@H]2F)nc1 CZQSEYWYGNEWBZ-RMSVRTADSA-N 0.000 description 1
- MIVYGBNHFGFZNE-FUHWJXTLSA-N CCc1cnc(N(CC[C@H]2N(C3CC3)C(c(nc3)cnc3-[n]3ncnc3)=O)C[C@@H]2F)nc1 Chemical compound CCc1cnc(N(CC[C@H]2N(C3CC3)C(c(nc3)cnc3-[n]3ncnc3)=O)C[C@@H]2F)nc1 MIVYGBNHFGFZNE-FUHWJXTLSA-N 0.000 description 1
- BJWDVPYQXJCEQC-VQTJNVASSA-N CCc1cnc(N(CC[C@H]2N(C3CC3)C(c3cnc(-[n]4c(C)ncc4)nc3)=O)C[C@@H]2F)nc1 Chemical compound CCc1cnc(N(CC[C@H]2N(C3CC3)C(c3cnc(-[n]4c(C)ncc4)nc3)=O)C[C@@H]2F)nc1 BJWDVPYQXJCEQC-VQTJNVASSA-N 0.000 description 1
- NZYOGBPIJUCENG-UHFFFAOYSA-N COC(C1)(C(OC)=O)ON=C1c(ccc(C#N)c1)c1F Chemical compound COC(C1)(C(OC)=O)ON=C1c(ccc(C#N)c1)c1F NZYOGBPIJUCENG-UHFFFAOYSA-N 0.000 description 1
- ZQWUUPBHODOKMW-UHFFFAOYSA-N CS(c(cc1)ccc1-c(cc1)ncc1C(N(C1CC1)C(CC1)CCN1C#N)=O)(=O)=O Chemical compound CS(c(cc1)ccc1-c(cc1)ncc1C(N(C1CC1)C(CC1)CCN1C#N)=O)(=O)=O ZQWUUPBHODOKMW-UHFFFAOYSA-N 0.000 description 1
- RCHXPUNNONXPFJ-UHFFFAOYSA-N CS(c(cc1)ccc1-c(nc1)ncc1C(N(C1CC1)C1CCNCC1)=O)(=O)=O Chemical compound CS(c(cc1)ccc1-c(nc1)ncc1C(N(C1CC1)C1CCNCC1)=O)(=O)=O RCHXPUNNONXPFJ-UHFFFAOYSA-N 0.000 description 1
- PSOZJOZKEVZLKZ-UHFFFAOYSA-N Cc1c[o]c(C)n1 Chemical compound Cc1c[o]c(C)n1 PSOZJOZKEVZLKZ-UHFFFAOYSA-N 0.000 description 1
- LCZUOKDVTBMCMX-UHFFFAOYSA-N Cc1cnc(C)cn1 Chemical compound Cc1cnc(C)cn1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 1
- CYGOSSQUEMVYHG-UHFFFAOYSA-N Cc1cnc(N(CC2)CCC2NC2CC2)nc1 Chemical compound Cc1cnc(N(CC2)CCC2NC2CC2)nc1 CYGOSSQUEMVYHG-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
- FZAXBPZVVJOFKX-UHFFFAOYSA-N Cc1n[o]cn1 Chemical compound Cc1n[o]cn1 FZAXBPZVVJOFKX-UHFFFAOYSA-N 0.000 description 1
- MLPCMXYDRKUMGD-UHFFFAOYSA-N Cc1ncc[n]1-c(nc1)ncc1C(N(C1CC1)C(CCN(C1)c2ccc(C(F)(F)F)cn2)C1F)=O Chemical compound Cc1ncc[n]1-c(nc1)ncc1C(N(C1CC1)C(CCN(C1)c2ccc(C(F)(F)F)cn2)C1F)=O MLPCMXYDRKUMGD-UHFFFAOYSA-N 0.000 description 1
- IDQXGDSGPZNQTN-PKOBYXMFSA-N Cc1ncc[n]1-c1ncc(C(N(C2CC2)[C@H](CCN(C2)c3ccc(C(F)(F)F)cn3)[C@H]2F)=O)nc1 Chemical compound Cc1ncc[n]1-c1ncc(C(N(C2CC2)[C@H](CCN(C2)c3ccc(C(F)(F)F)cn3)[C@H]2F)=O)nc1 IDQXGDSGPZNQTN-PKOBYXMFSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ncccc1 Chemical compound Cc1ncccc1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N Cc1nccnc1 Chemical compound Cc1nccnc1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- DRSCBBSCLOQJIA-UHFFFAOYSA-N FC(c1cc(F)c(N(CC2)CCC2NC2CC2)nc1)(F)F Chemical compound FC(c1cc(F)c(N(CC2)CCC2NC2CC2)nc1)(F)F DRSCBBSCLOQJIA-UHFFFAOYSA-N 0.000 description 1
- BGZZTHSVOJZJEG-UHFFFAOYSA-N O=C(c(nc1)cnc1-[n]1ncnc1)N(C1CC1)C(CCN(C1)c2ccc(C(F)(F)F)cn2)C1F Chemical compound O=C(c(nc1)cnc1-[n]1ncnc1)N(C1CC1)C(CCN(C1)c2ccc(C(F)(F)F)cn2)C1F BGZZTHSVOJZJEG-UHFFFAOYSA-N 0.000 description 1
- LIVDOBRCIKCBIC-UHFFFAOYSA-N O=C(c1cnc(-[n]2cncc2)nc1)N(C1CC1)C(CC1)CCN1c1nc(-c2ccccc2)n[o]1 Chemical compound O=C(c1cnc(-[n]2cncc2)nc1)N(C1CC1)C(CC1)CCN1c1nc(-c2ccccc2)n[o]1 LIVDOBRCIKCBIC-UHFFFAOYSA-N 0.000 description 1
- DBVGKAMVRRIHQQ-UHFFFAOYSA-N O=C(c1cnc(-c2ccncc2)nc1)N(C1CC1)C(CC1)CCN1c1nc(-c2ccccc2)n[o]1 Chemical compound O=C(c1cnc(-c2ccncc2)nc1)N(C1CC1)C(CC1)CCN1c1nc(-c2ccccc2)n[o]1 DBVGKAMVRRIHQQ-UHFFFAOYSA-N 0.000 description 1
- ZFPKPRDCQBIPAY-UHFFFAOYSA-O [NH2+]=C(N(CC1)CCC1N(C1CC1)C(c1cnc(-[n]2cncc2)nc1)=O)/N=C(/C1CC1)\O Chemical compound [NH2+]=C(N(CC1)CCC1N(C1CC1)C(c1cnc(-[n]2cncc2)nc1)=O)/N=C(/C1CC1)\O ZFPKPRDCQBIPAY-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169297 | 2011-06-09 | ||
| EP11169297.6 | 2011-06-09 | ||
| PCT/EP2012/060729 WO2012168315A1 (en) | 2011-06-09 | 2012-06-06 | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516070A JP2014516070A (ja) | 2014-07-07 |
| JP2014516070A5 JP2014516070A5 (enExample) | 2015-07-23 |
| JP6094578B2 true JP6094578B2 (ja) | 2017-03-15 |
Family
ID=46245574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514056A Active JP6094578B2 (ja) | 2011-06-09 | 2012-06-06 | 代謝性障害の治療のためのgpr119モジュレーターとしての置換ピペリジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8921398B2 (enExample) |
| EP (1) | EP2718288B1 (enExample) |
| JP (1) | JP6094578B2 (enExample) |
| AR (1) | AR086895A1 (enExample) |
| WO (1) | WO2012168315A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5935154B2 (ja) | 2011-03-14 | 2016-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gpr119モジュレーターとしてのn−シクロプロピル−n−ピペリジニルベンズアミド |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのgpr119モジュレーターとしての置換ピペリジン |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP2015523404A (ja) * | 2012-08-02 | 2015-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | N−シクロプロピル−n−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 |
| JP6285937B2 (ja) * | 2012-09-25 | 2018-02-28 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 除草性および殺真菌性の5−オキシ置換3−フェニルイソオキサゾリン−5−カルボキサミドおよび5−オキシ置換3−フェニルイソオキサゾリン−5−チオアミド |
| MA45782B1 (fr) | 2016-07-28 | 2021-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
| WO2019145460A1 (en) | 2018-01-26 | 2019-08-01 | Idorsia Pharmaceuticals Ltd | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
| KR20210123337A (ko) * | 2019-01-31 | 2021-10-13 | 더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드 | 방향족 고리 또는 헤테로방향족 고리 화합물, 이의 제조 방법 및 이의 의학 용도 |
| WO2025128834A1 (en) * | 2023-12-15 | 2025-06-19 | Alterome Therapeutics, Inc. | Akt1 modulators |
| WO2025207620A1 (en) * | 2024-03-27 | 2025-10-02 | Alterome Therapeutics, Inc. | Akt1 modulators |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| AU2003277552A1 (en) | 2002-11-06 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor regulator |
| JP2008537953A (ja) | 2005-04-15 | 2008-10-02 | エラン ファーマシューティカルズ,インコーポレイテッド | ブラジキニンb1受容体拮抗作用に有用な新規化合物 |
| KR101415426B1 (ko) * | 2005-09-27 | 2014-07-04 | 아이알엠 엘엘씨 | 디아릴아민-함유 화합물 및 조성물, 및 c-kit 수용체의조절제로서의 그의 용도 |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| ATE476418T1 (de) * | 2006-06-08 | 2010-08-15 | Amgen Inc | Benzamidderivate und assoziierte verwendungen |
| WO2008025799A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
| JP2010520878A (ja) | 2007-03-08 | 2010-06-17 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性の調節剤としての化合物および組成物 |
| GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| GB0812649D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| MX342128B (es) * | 2008-12-24 | 2016-09-14 | Bial - Portela & C A S A | Compuestos farmaceuticos. |
| AU2010264720A1 (en) | 2009-06-24 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
| AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
| JP5794297B2 (ja) | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gpr119アゴニストとしてのピリダジノン |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| EA201300846A1 (ru) | 2011-01-21 | 2013-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Конденсированные дигидрофураны в качестве модуляторов gpr119, предназначенные для лечения диабета, ожирения и родственных нарушений |
| JP5935154B2 (ja) | 2011-03-14 | 2016-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gpr119モジュレーターとしてのn−シクロプロピル−n−ピペリジニルベンズアミド |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのgpr119モジュレーターとしての置換ピペリジン |
-
2012
- 2012-06-06 JP JP2014514056A patent/JP6094578B2/ja active Active
- 2012-06-06 US US13/489,557 patent/US8921398B2/en active Active
- 2012-06-06 WO PCT/EP2012/060729 patent/WO2012168315A1/en not_active Ceased
- 2012-06-06 EP EP12726611.2A patent/EP2718288B1/en active Active
- 2012-06-08 AR ARP120102062A patent/AR086895A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2718288B1 (en) | 2015-03-11 |
| WO2012168315A1 (en) | 2012-12-13 |
| EP2718288A1 (en) | 2014-04-16 |
| AR086895A1 (es) | 2014-01-29 |
| JP2014516070A (ja) | 2014-07-07 |
| US8921398B2 (en) | 2014-12-30 |
| US20130143892A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5935154B2 (ja) | Gpr119モジュレーターとしてのn−シクロプロピル−n−ピペリジニルベンズアミド | |
| JP6094578B2 (ja) | 代謝性障害の治療のためのgpr119モジュレーターとしての置換ピペリジン | |
| JP6011543B2 (ja) | 糖尿病、肥満および関連疾患の治療のためのgpr119モジュレーターとしての縮合ジヒドロフラン | |
| JP5703393B2 (ja) | 糖尿病、肥満および関連障害の治療のためのgpr119モジュレーターとしての縮合ジヒドロフラン | |
| CN103958495B (zh) | 作为gpr-119的调节剂的化合物 | |
| JP6066126B2 (ja) | 新規化合物、医薬組成物及びその使用 | |
| JP6136032B2 (ja) | 新規な2,3−ジヒドロ−フロ[2,3−c]ピリジン、Gタンパク質共役受容体GPR119のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 | |
| JP6263789B2 (ja) | N−シクロプロピル−n−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| JP6212827B2 (ja) | N−シクロプロピル−n−ピペリジニル−アミド誘導体、およびgpr119モジュレーターとしてのそれらの使用 | |
| JP2015523404A (ja) | N−シクロプロピル−n−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| JP6119081B2 (ja) | Gpr119に対するフロ[2,3−c]ピリジン活性物質 | |
| WO2015167309A1 (ko) | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150605 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150806 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161207 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170123 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6094578 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |